Implications of intermittent calcitriol therapy on growth and secondary hyperparathyroidism.
Secondary hyperparathyroidism is the most common skeletal lesion in pediatric patients undergoing maintenance dialysis. The present review summarizes a prospective randomized study that evaluated the biochemical and skeletal responses to intermittent calcitriol therapy in 33 pediatric patients on peritoneal dialysis with secondary hyperparathyroidism. Also, the effect of intermittent calcitriol therapy on linear growth was evaluated in 16 of 33 patients who had completed the clinical trial. Serum parathyroid hormone levels decreased by 62% from 648+/-125 pg/ml in patients treated with intermittent intraperitoneal (IP) calcitriol, and values remained unchanged from pre-treatment levels of 670+/-97 pg/ml with oral calcitriol therapy. Overall serum total and ionized calcium levels were higher in patients treated with IP calcitriol during the study. In contrast to these biochemical findings, the skeletal lesions of secondary hyperparathyroidism improved after 12 months of treatment in both groups and adynamic bone occurred in 33% of the patients. Z-scores for height decreased from -1.80 /-0.3 to -2.00+/-0.3, P<0.01, after 12 months of intermittent calcitriol therapy. Such findings suggest that an intermittent schedule of calcitriol administration adversely affects chondrocyte activity within epiphyseal cartilage in pre-pubertal children with end-stage renal disease.
Salusky
I B
IB
Department of Pediatrics, UCLA School of Medicine, Los Angeles, CA 90095, USA. isalusky@mednet.ucla.edu
Goodman
W G
WG
Kuizon
B D
BD
D000818:Animals; D001842:Bone and Bones / Q000473:pathology; D002117:Calcitriol / Q000008:administration & dosage* / Q000627:therapeutic use; D002120:Calcium Channel Agonists / Q000008:administration & dosage* / Q000627:therapeutic use; D002648:Child; D002657:Child Development / Q000187:drug effects*; D004334:Drug Administration Schedule; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy* / Q000473:pathology; D010530:Peritoneal Dialysis; D011627:Puberty; D016032:Randomized Controlled Trials as Topic
D002120:Calcium Channel Agonists; D002117:Calcitriol